- Home
- ZNTL vs RANI Comparison
ZNTL vs RANI Comparison
Compare ZNTL & RANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZNTL | RANI |
|---|---|---|
| Founded | 2014 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 156.7M | 126.8M |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ZNTL | RANI |
|---|---|---|
| Price | $2.49 | $1.38 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $6.60 | ★ $8.60 |
| AVG Volume (30 Days) | 623.6K | ★ 769.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 47.87 | 21.05 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $67,425,000.00 | $1,028,000.00 |
| Revenue This Year | N/A | $414.59 |
| Revenue Next Year | N/A | $30.15 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.01 | $0.39 |
| 52 Week High | $3.95 | $3.87 |
Technical Indicators
Market Signals| Indicator | ZNTL | RANI |
|---|---|---|
| Relative Strength Index (RSI) | 51.81 | 55.35 |
| Support Level | $1.27 | $1.31 |
| Resistance Level | $2.69 | $1.42 |
| Average True Range (ATR) | 0.17 | 0.09 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 55.17 | 79.07 |
Price Performance
Historical ComparisonAbout ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
About RANI Rani Therapeutics Holdings Inc.
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.